Global Drug Delivery Partnering Terms and Agreements 2014-2020


The Global Drug Delivery Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Drug Delivery Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.


This report provides details of the latest Drug Delivery agreements announced in the life sciences since 2014.


The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.


The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 1000 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Drug Delivery dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading Drug Delivery deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Drug Delivery deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2014. The chapter is organized by specific Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2014.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.


Key benefits


Global Drug Delivery Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:


  • In-depth understanding of Drug Delivery deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Drug Delivery dealmakers since 2014
  • Insight into terms included in a Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Drug Delivery Partnering Terms and Agreements 2014-2020 is intended to provide the reader with an in-depth understanding and access to Drug Delivery trends and structure of deals entered into by leading companies worldwide.


Drug Delivery Partnering Terms and Agreements includes:


  • Trends in Drug Delivery dealmaking in the biopharma industry since 2014
  • Analysis of Drug Delivery deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Drug Delivery deals
  • Access to Drug Delivery contract documents
  • Leading Drug Delivery deals by value since 2014
  • Most active Drug Delivery dealmakers since 2014


In Global Drug Delivery Partnering Terms and Agreements 2014-2020, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Drug Delivery Partnering Terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 1000 Drug Delivery deals.


Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Drug Delivery Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:


  • In-depth understanding of Drug Delivery deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Drug Delivery dealmakers since 2014
  • Insight into terms included in a Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Drug Delivery dealmaking


2.1. Introduction

2.2. Drug Delivery partnering over the years

2.3. Most active Drug Delivery dealmakers

2.4. Drug Delivery partnering by deal type

2.5. Drug Delivery partnering by therapy area

2.6. Deal terms for Drug Delivery partnering

2.6.1 Drug Delivery partnering headline values

2.6.2 Drug Delivery deal upfront payments7

2.6.3 Drug Delivery deal milestone payments

2.6.4 Drug Delivery royalty rates


Chapter 3 – Leading Drug Delivery deals


3.1. Introduction

3.2. Top Drug Delivery deals by value


Chapter 4 – Most active Drug Delivery dealmakers


4.1. Introduction

4.2. Most active Drug Delivery dealmakers

4.3. Most active Drug Delivery partnering company profiles


Chapter 5 – Drug Delivery contracts dealmaking directory


5.1. Introduction

5.2. Drug Delivery contracts dealmaking directory


Chapter 6 – Drug Delivery dealmaking by technology type


Chapter 7 – Partnering resource center


7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking




Appendix 1 – Drug Delivery deals by company A-Z


Appendix 2 – Drug Delivery deals by stage of development




Phase I

Phase II

Phase III





Appendix 3 – Drug Delivery deals by deal type


Asset purchase


Bigpharma outlicensing


Collaborative R&D







Equity purchase



Joint venture





Material transfer





Spin out



Technology transfer




Appendix 4 – Drug Delivery deals by therapy area


Appendix 5 –Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures

Figure 1: Drug Delivery partnering since 2014

Figure 2: Active Drug Delivery dealmaking activity since 2014

Figure 3: Drug Delivery partnering by deal type since 2014

Figure 4: Drug Delivery partnering by disease type since 2014

Figure 5: Drug Delivery deals with a headline value

Figure 6: Drug Delivery deals with an upfront value

Figure 7: Drug Delivery deals with a milestone value

Figure 8: Drug Delivery deals with a royalty rate value

Figure 9: Top Drug Delivery deals by value since 2014

Figure 10: Most active Drug Delivery dealmakers since 2014

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3DMed, 3M Drug Delivery Systems, 3P Biopharmaceuticals, 3PrimeDx, 3SBio, A*STAR Agency for Science, Technology and Research, A1 Group, AADi, Abbott Laboratories, Abbvie, Abcam, Abiogen Pharma, Absorption Systems, Acacia Pharma, Accelis Pharma, Accord Healthcare, Acella Pharmaceuticals, Acelrx Pharmaceuticals, Acerus, Aceto Corporation, Ache, Aclaris Therapeutics, Acorda Therapeutics, Actavis (acquired by Watson), Actelion, Acuity Pharmaceuticals, Acura Pharmaceuticals, AdAlta, Adama, Adamas Pharmaceuticals, Adamis Pharmaceuticals, Adaptive Health, Adapt Pharma, Adare Pharmaceuticals, Adhesys Medical, Adhezion Biomedical, Admedus, Advanced Catheter Therapies, Advanced Cooling Therapy, Advanced Dosage Forms, Advanced Medical Solutions, Advaxis, Adverum Biotechnologies, Aegis Therapeutics, Aequus Pharmaceuticals, Aerie Pharmaceuticals, Aerogen, Aeromics, Aero Pump, AEterna Zentaris, Afaxys Pharmaceuticals, AFT Pharmaceuticals, Agalimmune, Aires Pharmaceuticals, AIT Therapeutics, Ajad Medical, Akorn, Akrivis Technologies, Albany Molecular Research, Albion, Albumedix, Alcyone Lifesciences, Alexion Pharmaceuticals, Alexza Pharmaceuticals, Alfa Wassermann, Aligo, Alimera Sciences, ALK-Abello, Allergan, Allergan (name changed from Actavis), Alliance for Lupus Research, AllianceRx Walgreens Prime, Allied Corp, Allogene Therapeutics, AlloSource, Almirall, Alnylam Pharmaceuticals, Alphamab Biopharmaceuticals, ALRISE Biosystems, ALS Association, Alteogen, Altimmune, Altum Pharmaceuticals, Altus Formulation, Aluna, Alvit LCS Pharma, Alvogen, Alzyn, Amarantus BioSciences, Amedica, American CryoStem, American Diabetes Association, Amerigen Pharmaceuticals, Amerinet, AmerisourceBergen, Amgen, AMI, Amneal Pharmaceuticals, AMPEL BioSolutions, AMSL, Amunix, Anacor Pharmaceuticals, ANANDA Scientific, Andor Pharmaceuticals, Angelini Pharma, AnGes MG, Anika Therapeutics, ANI Pharmaceuticals, Anji Pharma, Antares Pharma, Anteis, AntiOp, Apellis Pharmaceuticals, Aphria, AppianRx, Applied DNA Sciences, APR Applied Pharma Research, Aprecia Pharmaceuticals, Apricus Biosciences, Apsen Farmacutica, Aptar Pharma, Aquestive Therapeutics, Aralez Pharmaceuticals, Arbutus, Arcoral Pharma, Arctic Vision, Arcturus Therapeutics, Arecor, Argentum Pharmaceuticals, argenx, Aries Pharmaceuticals, Arisaph Pharmaceuticals, Armas Pharmaceuticals, Arsia Therapeutics, Artes Biotechnology, Art of Technology, Asahi Kasei, Asahi Kasei Kuraray Medica, Ascendia Pharmaceuticals, Ascend Therapeutics, Ascensia Diabetes Care, Asieris MediTech, Asklepios Biopharmaceutical, Aspen Global, Aspen Pharmacare Canada, Astellas Pharma, Astellas Pharma Europe, AstraZeneca, Athenex, Atlangram, Aucta Pharmaceuticals, Audentes Therapeutics, Aura Biosciences, Auris Medical, Aurora Cannabis, AusHealth, Auspherix, Austrianova Singapore, Autotelic, Auxilium Pharmaceuticals, Auxly Cannabis Group, Avacta, Avalanche Biotechnologies, Avanos Medical, Avara Pharmaceutical Services, AV Cannabis, Avectas, Avellino Labs, Avenue Therapeutics, Avidity NanoMedicines, Avion Pharmaceuticals, Avior Bio, Aviragen Therapeutics, Avita Medical, AXIM Biotechnologies, Aytu BioScience, Azaya Therapeutics, BASF, Bausch & Lomb, Bausch Health Companies, Baxter International, Bayer, Bayer Healthcare, Bazelet, B Braun, BDD Pharma, Becton Dickinson, Bedford Laboratories, Beijing Double-Crane Pharmaceutical, Beijing Keyuan Xinhai Pharma, Bellerophon Therapeutics, Bellicum Pharmaceuticals, Ben-Gurion University, Ben Venue Laboratories, Berlin-Brandenburg Center for Regenerative Therapies, Berlin Chemie, Besins Healthcare, Bespak, Best Choice, Betaliq, BevCanna, BGN Technologies, Bigfoot Biomedical, Bill and Melinda Gates Foundation, BIND Therapeutics, BioArctic Neuroscience, biOasis Technologies, BioCardia, BIOCORP, BioCorRx, Biodel, BioDelivery Sciences, Bio DG, Biogen, Biohaven Pharmaceutical Holding, Bioject Medical Technologies, BiolineRX, BioLingus, Biological E, Biologix FZCo, Biomedical Advanced Research and Development Authority, BioNTech, Biophage Pharma, BioPharm Group International, BiopharmX, BioQ Pharma, Biosensors International, Bioventus, Birdie Biopharmaceuticals, BLP Management, BlueWillow Biologics, BMG Pharmaceuticals, Boehringer Ingelheim, Bora Pharmaceuticals, Boston Topicals, Bpifrance, Braeburn Pharmaceuticals, Breathe ECig, Breckenbridge Pharmaceutical, Breckenridge Pharmaceuticals, BridgeBio Pharma, Bridge Medicines, BrightFocus Foundation, Brill Pharma, Bristol-Myers Squibb, BRNT, Broda Technologies, Bryn Pharma, C-Tri, Cadila Pharmaceuticals, Calidi Biotherapeutics, California Institute for Biomedical Research, Camargo Pharmaceutical Services, Camarus, Cam Med, Camurus, Canada-Israel Industrial R&D Foundation, Cancer Prevention and Research Institute of Texas, Candela, Canigma, Cannabics Pharmaceuticals, Cannabis Science, CannaKids, CannaRoyalty, CannaSkin, Cannassure Therapeutics, CanniMed Therapeutics, CannPal Animal Therapeutics, CannRx Technology, CannScience Innovations, Canntab Therapeutics, Canopy Growth, Cantabria Pharma, Capcium, Capillary Biomedical, Capna Intellectual, Capnia, Capricor Therapeutics, Caprion Proteomics, Cara Therapeutics, Cardinal Health, Cardiome Pharma, Cardiovascular Systems, Caris Life Sciences, Carisma Therapeutics, Carlina Technologies, Carna BioSciences, Carpal Aid, CarThera, CASI Pharmaceuticals, Catalent, Cataract & Laser Institute, CBDerma Technology, CBx Data Labs, CEA-Leti, Ceapro, Cedars-Sinai Medical Center, Celator, Celdara Medical, Celgene, Cell Care Therapeutics, Cellectar Biosciences, Celling Biosciences, CellProThera, Celon Pharma, Cel Sci, Central Admixture Pharmacy Services, Centre for Commercialization of Regenerative Medicine (CCRM), Centro de Investigación Biomédica en Red de Salud Mental, Cequr, Cerebral Therapeutics, Cerenis Therapeutics, Cerner, Charite-Universitatsmedizin, Chemesis, ChemWerth, Cheplapharm Arzneimittel, Chiesi Farmaceutici, Children's Hospital of Philadelphia, Children's National Medical Center, Chimerix, China Medical System, China Resources Guokang Pharmaceuticals, Chinese Academy of Sciences, Chiome Bioscience, Chrono Therapeutics, Cilian, Cingulate Therapeutics (CTx), Cipher Pharmaceuticals, Cipla, Circassia, Citius Pharmaceuticals, Clear Guide Medical, Clearside Biomedical, Cleveland Diabetes Care, Cleveland University Hospitals, Clinigen, Clinvest, CME Medical, CMIC, Cocoon Biotech, Codan Triplus, Coldstream Laboratories, Colep, Collegium Pharmaceuticals, Colorcon, Columbia Care, Columbia Laboratories, Columbia University, Common Sensing, Companion Medical, Concordia Pharmaceuticals, Consilient Health, Consortia Health Clinical Continence Services, Consort Medical, Context Therapeutics, ContraVir Pharmaceuticals, Convoy Therapeutics, Cook Biotech, Corium International, CorMedix, Cornerstone Animal Health, Coronado Biosciences, Correvio Pharma, Corsair Pharma, CorVascular, Corvida Medical, Cosmo Pharmaceuticals, Covance, Crescita Therapeutics, CRISPR Therapeutics, Cristal Therapeutics, Crown Laboratories, CR Pharma, CSIRO, CSL Behring, CTC Bio, CTT Pharmaceutical, CTX Technology, Cumberland Pharmaceuticals, Curadigm, CURE Pharmaceutical, Currax Pharmaceuticals, CURx Pharmaceuticals, Cutanea Life Sciences, CVS Caremark, CV Sciences, Cycle Pharmaceuticals, Cyclo Therapeutics, CyDex, Cynapsus Therapeutics, Cyndea Pharma, Cynosure, Cyrano Therapeutics, Cystic Fibrosis Foundation Therapeutics, Cystic Fibrosis Trust, CytImmune Science, D. Western Therapeutics Institute, Daiichi Sankyo, Dalhousie University, DanaLife, Dance Biopharm, DARA BioSciences, Dare Bioscience, DarioHealth, Dauntless Pharmaceuticals, DBV Technologies, Debiotech, Dechra Pharmaceuticals, Decibel Therapeutics, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Defymed, DEKA Research and Development, Delcath Systems, Delivra, Delpor, DelSiTech, Delta 9 Cannabis, Department of Defense, DepoMed, Dermira, Dexcel Pharma, DexCom, Dicerna Pharmaceuticals, Dipexium Pharmaceuticals, Dixie State University, DNAtrix, Domainex, Dorizoe Lifesciences, DOSE Medical, Dr. Reddy's Laboratories, Dr Bragi Company, Dr Kerklaan Therapeutics, Dukal, Durata Therapeutics, Durect, Dynasil, Eagle Pharmaceuticals, ECM Medical, ECM Therapeutics, Ecole Polytechnique Federale de Lausanne, Editas Medicine, Egalet, EirGen Pharma, Eisai, Eitan Group, Elasmogen, Elcelyx Therapeutics, Elektrofi, Eleven Biotherapeutics, Eli Lilly, Elite Pharmaceuticals, EMD Serono, Emerald Health Therapeutics, Emerge Health, Emergent BioSolutions, Emisphere, Empower Clinics, Emtora Biosciences, Enable Injections, Encore Medical, Endo International, Endo Pharmaceuticals, Endotronix, Endo Ventures, Enesi Pharma, enGene, Ensemble Therapeutics, Entegra Laboratories, Enteris Biopharma, Enterprise Therapeutics, Entos Pharmaceuticals, Envisia Therapeutics, Enzymatica, EOFlow, EPI Health, Eppin Pharma, Equashield, Espero Pharmaceuticals, Ethicon Endo-Surgery, Ethris, Eton Pharmaceuticals, Eu Hwa, Eurofarma, Eurolab Especialidades Medicinales de Eurofar, European Union, European Union Regional Development Fund, EUSA Pharma, Eve & Co, Everads Therapy, Eversana, Evestra, Evoke Pharma, Evonik Industries, Evox Therapeutics, Exactus, Exela Pharma Sciences, Exonate, ExxPharma Therapeutics, Eyegate Pharmaceuticals, EyePoint Pharmaceuticals, Eyevance, Fabre Kramer Pharmaceuticals, Fagron, Famy Care, Faron Pharmaceuticals, Fast Forward, Faulk Pharmaceuticals, Feldan Therapeutics, Ferndale Pharma Group, Ferrer International, Ferring Pharmaceuticals, Fidia Farmaceutici, Finch Therapeutics, Fine Foods & Pharmaceuticals N.T.M., Finnish Funding Agency for Technology and Innovation (TEKES), FirstString Research, Flamel Technologies, Flexion Therapeutics, Flextronics, Flower One, Flowonix, Flynn Pharma, Foamix Pharmaceuticals, Food and Drug Administration (FDA), Foresee Pharmaceuticals, Formac Pharmaceuticals, Fortify Therapeutics, Fougera Pharmaceuticals, Four 20 Pharma, Fred Hutchinson Cancer Research Center, Fresenius Kabi Pharmaceuticals, FSD Pharma, Fujifilm Pharma, Futura Medical, FX Therapeutics, G-treeBNT, Galderma, Galen, Galena Biopharma, Gallazzi, Galvani Bioelectronics, Gardia Medical, GB Sciences, GC Pharma, Gebro Pharma, Genco Sciences, GenEdit, Genentech, GeneQuine Biotherapeutics, Generex Biotechnology, Genetic Immunity, Genevant Sciences, Genexine, Genisphere, Genovi Pharmaceuticals, GenVec, Geo-Med, GeoVax, Gilead Sciences, Gland Pharma, Glaukos, GlaxoSmithKline, Glenmark Pharmaceuticals, Glialogix, Glide Technologies, Global Drug Development Centre (GDCC) China, Global Genomics Group, Global Medical Solutions, Globe Med Tech, Glooko, Goodwin Biotechnology, Government of Canada, GrayBug, Green Cross LabCell, Grenco Science, Grifols, Grunenthal, Grupo Ferrer, Guerbet, GVK Biosciences, GW Pharmaceuticals, H2-Pharma, Hainan Sinotau Pharmaceutical, Haisco Pharmaceutical, Halo Labs, Halo Pharmaceutical, Halozyme Therapeutics, Hapten Sciences, Harm Reduction Therapeutics, Harvard Medical School, Harvard University, Haselmeier, HCA Holdings, Health Canada, Healthcare Royalty Partners, Healthy Directions, Heat Biologics, HEC Pharm, Hefei Life Science, Hefei Tianhui Incubation of Technologies, Heidelberg Pharma, Helix BioPharma, Helsinn Healthcare, HemispheRx Biopharma, Heritage Pharmaceuticals, Heumann Pharma Generics, Hibernation Therapeutics, Highland Therapeutics, Hikma Pharmaceuticals, Hill Dermaceuticals, Hillstream BioPharma, HLH BioPharma Vertriebs, HLS Therapeutics, Hoffmann La Roche, Hollister Biosciences, Hologic, Hookipa Pharma, Horizon 2020, Horizon Pharma plc, Horus Pharma, Hospi, Hospira, Hoth Therapeutics, Hovione, Huons, Hyundai Pharmaceutical, iBIO Institute’s PROPEL Center, Icahn School of Medicine at Mount Sinai, ICAN, iCAN:Israel-Cannabis, ICB Pharma, Ice + Jam, iCeutica, Ichor Medical Systems, Idorsia, Ikaria, ImaginAb, Imbed Bio, Immune Design, Immune Pharmaceuticals, ImmunGene, Immunocore, ImmunoForge, Immunomic, Immunovaccine, Impax Laboratories, Imperial Brands, Impression Healthcare, Imprimis Pharmaceuticals, Inceptua, InCube Labs, Incyte, Indee Labs, Indivior, Inexia, Infectious Disease Research Institute (IDRI), InfusAID, Infuseon Therapeutics, InfuSystem Holdings, InfuTronix Solutions, Inhibrx, InMed Pharmaceuticals, Innovare, Innovate UK, Innovation Pharmaceuticals, Innovus Pharmaceuticals, Inolife Technologies, INO Therapeutics, Inovio Pharmaceuticals, InSite Vision, Inspirion Delivery Sciences, InspiRX Pharma, Instillo, Instituto de Ciencias Farmaceuticas, Insulet, InsuLine Medical, Insys Therapeutics, Intarcia Therapeutics, Intec, Integral BioSystems, Integra LifeSciences, Integrated Medical Systems, IntelGenx, Intellipharmaceutics, International Duchenne Alliance, Intract Pharma, Intralytix, Intratus, Intravacc, Inventia Healthcare, inVentiv Health, Invion, Ionis Pharmaceuticals, Ipsen, Iroko Pharmaceuticals, iSage Rx, ISA Pharmaceuticals, Israeli National Authority for Technological Innovation, Italfarmaco, iTeos Therapeutics, Iveria Technologies, ivWatch, Jacksonville Pharmaceuticals, Jade Therapeutics, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, Jazz Pharmaceuticals, Jiangsu Tainuo, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, JSC Pharmadis, Jubilant Hollisterstier, Julphar, Juniper Pharmaceuticals, Jupiter Orphan Therapeutics, Juvenile Diabetes Research Foundation, K2M, Kalgene Pharmaceuticals, Kali Care, Kalos Therapeutics, Kalytera Therapeutics, Kamada, Kanabo Research, Kancera, Kaneka, Karolinska Institute, Kastle Therapeutics, KC Pharmaceuticals, Keck Graduate Institute of Applied Life Sciences, KemPharm, Kimberly-Clark, Kindred Bio, Kinetic Concepts, Klaria, Knight Therapeutics, KODE Biotech, Konica Minolta, Kuhnil Pharmaceuticals, Kurve Technology, KVK-Tech, Kwang Dong Pharmaceutical, Kyorin Pharmaceutical, Laccure, Lachlan Pharma, La Jolla Pharmaceutical, Lannett, Lantheus Holding, LatAm Clinical Trials, Lauren Sciences, Leads Biolabs, Lee's Pharmaceutical, Leiden University, Leidos, Leiters, LeMaitre Vascular, Leon-nanodrugs, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, Leukocare, Lexaria Bioscience, LIDDS, Lifestyle Delivery Systems, Ligand Pharmaceuticals, Lightlake Therapeutics, Lineage Cell Therapeutics, Link Health, LIPAC Oncology, Lipidor, LipoCure, LipoMedics, Lobsor Pharmaceuticals, Locemia Solutions, Los Altos Pharmaceuticals, Lucideon, Luitpold Pharmaceuticals, Lumenis, LumiThera, Lumosa Therapeutics, Lunatus, Lupin Limited, Lupin Pharmaceuticals, Luye Pharma Group, Lyndra Therapeutics, Lyomark Pharma, Mallinckrodt Pharmaceuticals, MangoGen Pharma, Mannin Research, MannKind Biopharmaceuticals, Mapi Pharma, Marathon Pharmaceuticals, Marina Biotech, Marinomed Biotechnologie, Marinus Pharmaceuticals, Mark Foundation for Cancer Research, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mast Therapeutics, Matinas Biopharma, Mayne Pharma, Mayo Clinic, MBF Therapeutics, McCall MacBain Foundation, McMaster University, MD Anderson Cancer Center, MEAgate International, Meda, Medac, Med Alliance, Medherant, Medical Developments International, MedicaSafe, Medicines360, Medimetriks, MedImmune, MedinCell, Medinova, MediPharm Labs, Mediq, MediWound, Medline Industries, MedLite ID, MedPharm, Medtronic, Med Trust, Meiji Seika, Memorial Sloan Kettering Cancer Center, Menarini Asia-Pacific, MentiNova, Merck and Co, Merck KGaA, Merial, Meridian Medical Technologies, Meroven, Merrimack Pharmaceuticals, Merrion Pharmaceuticals, Merz, MetP Pharma, MHC Medical Products, Michael James Enterprises, Michael J Fox Foundation, Microchips Biotech, Microdermics, Micro Labs, Microlin Bio, MidaSol Therapeutics, Midatech, MilliporeSigma, Milo Biotechnology, Mimetogen Pharmaceuticals, MIM Software, MiNA Therapeutics, Miriam Hospital, Mission Pharmacal, Mitacs, Mitsubishi Tanabe Pharma, Moberg Pharma, Mobius Therapeutics, Moderna Therapeutics, Moebius Medical, Molecular Targeting Technologies, Molteni Farmaceutici, Monarch Biosciences, Monash University, MonoSol Rx, MonoSolRx, Morgan Stanley, Motif Bio, Movi, MSD, Mundipharma, Mylan Laboratories, Mylan Pharmaceuticals, MyLife Technologies, Mymetics, Myriad Genetics, Nanexa, Nanobiotix, Nanoform, Nanologica, Nanomerics, NanoPass Technologies, NanoProteagen, nanoRanch, NanoSmart Pharmaceuticals, NanoSphere Health Sciences, Nanotechnology Characterization Laboratory, NantBioScience, NantPharma, NapaJen Pharma, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Green Biomed, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Medical Products, National Research Council Industrial Research Assistance Program, National Research Council of Canada, National Science Foundation, Natural Sciences and Engineering Research Council of Canada, Navamedic, Navidea Biopharmaceuticals, Nemaura Medical, Nemaura Pharma, NEMUS Bioscience, Neos Therapeutics, Nephron Dx, Nephron Pharmaceuticals, Nestle Health Science, Neurimmune Therapeutics, Neurim Pharmaceuticals, NeuroOne, NeuroVive Pharmaceutical, NeuRx Pharmaceuticals, Nevada Center For Behavioral Health, NewCanna Hub, Newsummit Biopharma, New York State, New York University, New York University School of Medicine, Nextleaf Solutions, Nextremity Solutions, Nicox, Nightstar Therapeutics, NitricGen, Nitto Denko, NLS Pharmaceutics, Nocion Therapeutics, Nordic Pharma Group, North Carolina State University, NovaBay Pharmaceuticals, Novaceutical Sciences, Novalere, Novaliq, Novan Therapeutics, Novarix, Novartis, Novartis Consumer Health, Novation, Novo Nordisk, Novoteris, Novozymes Biopharma, NSW Medical Device Fund, NTC, Nu-med Plus, Nucorion, NuMedii, Nuritas, Nutriband, Nuvilex, Nuvo Pharmaceuticals, Nuvo Research, NZMS, Oakrum Pharma, OBJ, Ocular Therapeutics, Ocular Therapeutix, Oculis, Ocumension Therapeutics, Ohio State University, Ohr Pharmaceuticals, Olympus Medical Systems, Omega Pharma, Omeq Medical, Omeros, Omnicell, Oncology Pharma, OncoNano Medicine, Onconova Therapeutics, OncoSec Medical, Oncosynergy, OnDosis, Ono Pharmaceutical, Onxeo, Ophthotech, Opiant Pharmaceuticals, OPKO Health, OptiBiotix, Optimist Inhaler, OptiNose, Optos, Oramed Pharmaceuticals, Orapharma, Orbis, Orbit Biomedical, Orchestra BioMed, Orexigen Therapeutics, Orexo, Organogenesis, Orgenesis, Orimed Pharma, Orion, Orphan Europe, Orsini Healthcare Specialty Pharmacy, Osivax, Osmotica Pharmaceuticals, Ossianix, OsteoRemedies, Otifex Therapeutics, Otonomy, Otsuka, Ovensa, OWC Pharmaceutical Research, Owen Mumford, Oxygen Plus, OxySure Systems, Pace Wellness, Palvella Therapeutics, Panaxia, Panther Biotechnology, Paragon BioTeck, PARI Pharma, Parker Hannifin, Par Pharmaceutical, Particle Sciences, Patara Pharma, Patheon, PATH Malaria Vaccine Initiative, Pax Labs, Pax Neuroscience, PDL BioPharma, PellePharm, PeptiDream, Peptron, Pernix Therapeutics, Perrigo, Pfizer, Phagelux, Pharmaceutics International, Pharmacyclics, PharmaEngine, PharmaIN, PharmaJet, Pharmalink AB, PharmaLynk, Pharmanest, Pharmastrip, Pharmathen, Pharmatronic, Pharos Life Corporation, Pherin Pharmaceuticals, Phibro Animal Health, Phico Therapeutics, Phillips-Medisize, Phio Pharmaceuticals, Phosphagenics, Photocure ASA, PhytoTech Medical, PIC, Picosun, Piedmont Pharmaceuticals, Pierre Fabre, Pierre Fabre Dermatologie, Pillar Palatal, PillTracker, Piramal, Pivot Pharmaceuticals, PixarBio, Planet Wheeler Foundation, PlantEXT, Plethora Solutions, Pneuma Respiratory, Pohl Boskamp, Polyganics, Polypeptide Therapeutic Solutions, Polyphor, Population Council, Portage Glasgow, Portage Pharmaceuticals, Portal Instruments, Prasco Laboratories, Praxis, Preceyes, Precisa Medical Instruments, Precision Ocular, Premier Inc, Preora Diagnostics, Presage Biosciences, Prestium Pharma, Principle Business Enterprises, Privo Technologies, ProBioGen, Processa Pharmaceuticals, Profusa, ProLynx, Promius Pharma, Propeller Health, Pro Pharmaceuticals, Prosonix, Proveca, ProvideGx, Proximagen Group, Proxy Biomedical, pSivida, Public Health England, Pulmatrix, Pulmonox, Purdue Pharma, Purdue University, PureTech Health, Pyramid Biosciences, Quad Technologies, Quanta, Questcor Pharmaceuticals, Quintiles, QuiO Technologies, Quotient Clinical, Rafa Pharmaceuticals, Rani Therapeutics, Ra Pharmaceuticals, Rapid Dose Therapeutics, Raptor Pharmaceutical, Rechon Life Sciences, Recipharm, Reckitt Benckiser, Recordati, Recordati Espana, RedHill Biopharma, Redwood Pharma, ReForm Biologics, Regeneron Pharmaceuticals, Regenerx, Regeneus, RegenLab, Regenxbio, Regis Technologies, ReLeaf Europe, Relmada Therapeutics, Renaissance Acquisition Holdings, ReNeuron, Renovacare, Replicel Life Sciences, Respirent Pharmaceuticals, Respironics, Revogenex, Rexahn Pharmaceuticals, Rhinomed, Rhythm Pharmaceuticals, Rising Pharmaceuticals, Roche, Roivant Sciences, Roswell Park Cancer Institute, RoverMed BioSciences, Royal Philips Electronics, RRD International, Rubin Medical, Rutgers University, RXi Pharmaceuticals, Sagent Pharmaceuticals, Salient Surgical Technologies, Salix Pharmaceuticals, Samsung Electronics, Sandoz, Sanofi, Sanofi-Pasteur, Santen Pharmaceutical, Sanuwave Health, Saol Therapeutics, Saraya, Sartorius Stedim Biotech, Sato Pharmaceutical, Savara Pharma, Sawai Pharmaceuticals, Scandinavian Health, Scholar Rock, Schott, Sciecure Pharma, Science Foundation Ireland, scPharmaceuticals, Secarna Pharmaceuticals, Sedor Pharmaceuticals, Seelos Therapeutics, SELLAS Life Sciences Group, SemaThera, Sementis, Senju Pharmaceutical, Sentynl Therapeutics, Senzer, Seqirus, SeraNovo, SerenaGroup, Seurat Therapeutics, Sevion Therapeutics, SFC Fluidics, Shilpa Medicare, Shin Nippon Biomedical Laboratories, Shionogi, Shire Pharmaceuticals, SignaBlok, Signum Biosciences, Simcere Pharmaceuticals, Simulations Plus, Sinopharm, Sinotherapeutics, Sintact Medical Systems, Sirtex Medical, SiSaf, Skinvisible, SKS Ocular, SkyePharma, Skyline Vet Pharma, Small Business Innovation Research, SMG Pharmaceuticals, Smith Medical Partners, Smiths Medical, Snoring Center USA, Soin Neuroscience, Solasia Pharma, Soligenix, Solmic Research, SomaServe, Sono-Tek, Sonoma Pharmaceuticals, Sonrgy, Sophos Biotech, Sorrento Therapeutics, Sorse technology, Sosei, Sosei Heptares, Sothema Laboratories, Southwest Research Institute, Spark Therapeutics, Sparsha, Spaulding Clinical Research, Spear Pharmaceuticals, Specialised Therapeutics, Spectrum Pharmaceuticals, SpePharm, SpineThera, SPI Pharma, SQ Innovation, SRI International, STADA Arzneimittel, Stanford University, Starpharma, StemCell Systems, Sterifarma, Stevanato, Stiefel Laboratories, Strategic Science and Technologies, Sundial Growers, SunGen, Sunovion Pharmaceuticals, Sun Pharmaceutical, Sunstar Suisse, Supreme Cannabis, Suven Life Sciences, Suzhou NeuPharma, SymBio Pharmaceuticals, Synartro, Synthetic Biologics, Syqe Medical, Tabuk Pharmaceutical, Tactical Relief, Taiho, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda Pharmaceutical, Tandem Diabetes Care, Tanner Pharmaceuticals, Targeted Therapy Technologies, Taro Pharmaceuticals, Tauriga Sciences, Technology Strategy Board (UK), TEDOR Pharma, Teewinot Life Sciences, Teijin, Teikoku Pharma USA, Tekmira Pharmaceuticals, Tekni-Plex, Teligent, Telix Pharmaceuticals, Temple University, TerrAscend, TerSera Therapeutics, Terumo, Terumo BCT, Tesaro, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, TFB & Associates, TFS Corporation, The Alchemists Kitchen, The Kroger, The Medicines Company, TheraBiologics, Therakine, Therakos, Theramex, TherapeuticsMD, Therapix Bio, Therios Healthcare, Thin Film Electronics, Third Pole Therapeutics, Thomas Jefferson University, Threshold Pharmaceuticals, Thrive Cannabis, Tidepool, Tissue Regenix Group, Titan Pharmaceuticals, to-BBB Technologies, TONIX Pharmaceuticals, Toray, Tramorgan, Transdermal Delivery Solutions, Transporin, Trevi Therapeutics, Trimel Pharmaceuticals, Trinity Compound Solutions, Tripex Pharmaceuticals, Tris Pharma, Tritech, TRPharm, TRX Wound Care, TSRL, Turing Pharmaceuticals, Turku PET Center, twoXAR, Tyligand Bioscience, TypeZero Technologies, Ubiquigent, UCB, UDG Healthcare, Ultragenyx Pharmaceuticals, Uluru, Unilife, Unistraw Holding, United Therapeutics, Universidad de Cadiz, Universidad De Sevilla, Universidad de Seville, University Health Network, University of Alabama at Birmingham, University of Bern, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of Chicago, University of Cologne, University of Colorado, University of Edinburgh, University of Geneva, University of Glasgow, University of Liverpool, University of Manchester, University of Maryland, University of Massachusetts, University of Minnesota, University of Missouri, University of Northern Colorado, University of North Texas, University of Notre of Dame, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Sydney, University of Texas, University of Washington, Uppsalagruppen Medical, Upsher-Smith, UroGen Pharma, Ursapharm, US Army Medical Research and Material Command, US Bioservices, US Department of Veteran Affairs, US Government, Vaccibody, Valeant Pharmaceuticals, Valens GroWorks, Valeo Pharma, Valeritas, Vancive Medical Technologies, Vapium, Vasamed, Vaxart, Vaxess Technologies, VBI Vaccines, V ClinBio, Vect-Horus, Vectura, Verily, VeriTeQ, Vertical Pharmaceuticals, Vesselon, Vetter, Vianex, Vical, ViiV Healthcare, Vinnova, Virpax Pharmaceuticals, VisionCare Ophthalmic Technologies, VistaGen Therapeutics, Vitruvias Therapeutics, VivaCell Biotechnology Espana, Vizient, Vyera Pharmaceuticals, W.R.Grace, Walter Reed Army Institute of Research, Warner Chilcott, Watson Laboratories, Wellman Center For Photomedicine, West Pharmaceutical Services, Windgap Medical, Winhealth Pharma Group, Wirthlin-Denton, Wize Pharma, World Health Organization, Worldwide Clinical Trials, WOUNDCHEK Laboratories, WuXi Biologics, Wuxi STA, Xbrane Bioscience, Xcede Technologies, Xellia Pharmaceuticals, Xenon Pharmaceuticals, XERIS Pharmaceuticals, Xisle Pharma Ventures Trust, XL-Protein, Yale University, Yeda Research and Development Company, Yew Bio-Pharm, Yissum Research Development, Yom Chai, Ypsomed, ZappRx, Zenabis, Zhejiang Haichang Biotechnology, Zimmer Biomet, Zogenix, Zomedica, Zosano Pharma, Zyla Life Sciences, Zylera Pharmaceuticals, Zylo Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.